Brigatinib for ALK-positive metastatic non-small-cell lung cancer: Design, development and place in therapy

Robert Ali; Junaid Arshad; Sofia Palacio; Raja Mudad

doi:10.2147/DDDT.S147499

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: Design, development and place in therapy

Robert Ali, Junaid Arshad, Sofia Palacio, Raja Mudad

Medicine

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC.

Original language	English (US)
Pages (from-to)	569-580
Number of pages	12
Journal	Drug design, development and therapy
Volume	13
DOIs	https://doi.org/10.2147/DDDT.S147499
State	Published - 2019

Keywords

ALK inhibitors
ALK positive
Brigatinib
Non-small cell lung cancer
TKI

ASJC Scopus subject areas

Pharmacology
Pharmaceutical Science
Drug Discovery

Access to Document

10.2147/DDDT.S147499

Fingerprint Dive into the research topics of 'Brigatinib for ALK-positive metastatic non-small-cell lung cancer: Design, development and place in therapy'. Together they form a unique fingerprint.

Cite this

@article{ffbb0f9a525540e0aca9e5834a3ea76d,

title = "Brigatinib for ALK-positive metastatic non-small-cell lung cancer: Design, development and place in therapy",

abstract = "Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC.",

keywords = "ALK inhibitors, ALK positive, Brigatinib, Non-small cell lung cancer, TKI",

author = "Robert Ali and Junaid Arshad and Sofia Palacio and Raja Mudad",

note = "Publisher Copyright: {\textcopyright} 2019 Ali et al.",

year = "2019",

doi = "10.2147/DDDT.S147499",

language = "English (US)",

volume = "13",

pages = "569--580",

journal = "Drug Design, Development and Therapy",

issn = "1177-8881",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Brigatinib for ALK-positive metastatic non-small-cell lung cancer

T2 - Design, development and place in therapy

AU - Ali, Robert

AU - Arshad, Junaid

AU - Palacio, Sofia

AU - Mudad, Raja

PY - 2019

Y1 - 2019

N2 - Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC.

AB - Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC.

KW - ALK inhibitors

KW - ALK positive

KW - Brigatinib

KW - Non-small cell lung cancer

KW - TKI

UR - http://www.scopus.com/inward/record.url?scp=85062167362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062167362&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S147499

DO - 10.2147/DDDT.S147499

M3 - Review article

C2 - 30804663

AN - SCOPUS:85062167362

VL - 13

SP - 569

EP - 580

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: Design, development and place in therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this